Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: Evidence for reductive activation by cytochromes P450 1A1 and 1A2

Chemical Research in Toxicology

Volumn 14, Issue 8, 2001, Pages 1128-1137

  Stiborova M ^a   Frei, E ^b   Wiessler, M ^b   Schmeiser, H H ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; CARCINOGEN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; MICROSOME ENZYME; THIOCTIC ACID;

ANIMAL CELL; ARTICLE; BACULOVIRUS; CATALYSIS; CONTROLLED STUDY; DNA ADDUCT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LIVER MICROSOME; NONHUMAN; RAT; UROGENITAL TRACT CANCER; XENOBIOTIC METABOLISM;

ANIMALS; ARISTOLOCHIC ACIDS; CARCINOGENS; CATALYSIS; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DNA ADDUCTS; GENE EXPRESSION REGULATION; HUMANS; MALE; MICROSOMES, LIVER; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; PHENANTHRENES; PHOSPHORUS RADIOISOTOPES; RATS; RATS, WISTAR; SWINE;

EID: 0034861029     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx010059z     Document Type: Article

References (53)

1. Rapidly progressive intestitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs
2. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy
3. 32P-postlabeling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy
4. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy
5. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi)
6. Misuse of herbal remedies: The case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy)
7. Chinese herbs nephropathy or the evils of nature
8. 32P-postlabeling analysis using different chromatographic procedures
9. 32P-postlabeling in target and nontarget organs in rats treated with aristolochic acid I
10. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues
11. Urothelial malignancy in nephropathy due to Chinese herbs
12. Chinese herb nephropathy and renal pelvic carcinoma
13. Belgian (Chinese herb) nephropathy: Why?
14. Urothelial lesions in Chinese-herb nephropathy
15. Metabolic polymorphism and cancer susceptibility
16. 32P-postlabeling: Evidence for reductive activation by peroxidases
17. Mutagenicity of the two main components of commercially available carcinogenic aristolochic acids in Salmonella typhimurium
18. 32P-postlabeling of DNA adducts derived from peroxidative activation of carcinogenic non-aminoazo dye 1-phenylazo-2-hydroxynaphthalene (Sudan I)
19. Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples
20. N-hydroxylation enzymes of carcinogenic aminoazo dyes: Possible involment of cytochrome P-448
21. Metabolism of diamantane by rat liver microsomal cytochrome P-450
22. Metabolism of nitrosamines by purified rabbit liver cytochrome P-450 isozymes
23. Investigation of the bicinchoninic acid protein assay: Identification of the groups responsible for color formation
24. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
25. Dealkylation of pentoxyresorufin: A rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat
26. Oxidation of toxic and carcinogenic chemicals by human cytochrome P450 enzymes
27. An electron transport system associated with the outer membrane of liver mitochondria
28. Identification of the high and low potential flavins of liver microsomal NADPH-cytochrome P450 reductase
29. Purification to homogeneity and characterization of a form of cytochrome P-450 with high specificity for benzo[a]pyrene from β-naphthoflavone-pretreated rat liver microsomes
30. NADPH-cytochrome c (P450) reductase: Spectrophotometric and stopped flow kinetic studies on the formation of reduced flavoprotein intermediates
31. Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: A series of substrates to distinguish between different induced cytochromes P-450
32. Benzenediazonium ion derived from Sudan I forms an 8-(phenylazo)guanine adduct in DNA
33. Mechanism of formation and structural characterization of DNA adducts derived from peroxidative activation of benzidine
34. Selective inhibitors of cytochromes P450
35. Reversible inhibition of NADPH-cytochrome P450 reductase by alpha-lipoic acid
36. 32P-postlabeling test for structurally diverse DNA adducts
37. 32P-adduct assay comparative recoveries of structurally diverse DNA adducts in the various enhancement procedures
38. DNA adduct formation of aristolochic acid I and II in vitro and in vivo
39. 32P-labeled nucleoside 3′,5′-bisphosphate adducts of polycyclic aromatic hydrocarbons
40. 32P-postlabeling and high-pressure liquid chromatographic analyses for 7,12-dimethylbenz[a]anthracene-DNA adducts
41. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA
42. 6-adenyl arylation of DNA by aristolochic acid II and a synthetic model for the putative proximate carcinogen
43. Interaction between cytochrome P450 and cytochrome b5
44. 32P-postlabeling analysis of DNA adducts formed by aristolochic acid I and II
45. Comparative metabolism of 1-, 2-, and 4-nitropyrene by human hepatic and pulmonary microsomes
46. Metabolism of nitro-polycyclic aromatic hydrocarbons
47. Reduction of nitro and 9-oxo groups of environmental nitrofluorenes by the rat mammary gland in vitro
48. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors
49. Msp-1 polymorphism detected with a cDNA probe for the P450 I family on chromosome 15
50. Genetic linkage of lung cancer associated Msp1 polymorphism with amino acid replacement in the heme binding region of the human cytochrome P4501A1 gene
51. Acetylation phenotype and cytochrome-P4501A2 phenotype are unlikely to be associated with peripheral arterial disease
52. Human cytochrome P4501A2